Lv1
30 积分 2020-10-04 加入
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
2个月前
已完结
Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus Immunotherapy and targeted therapy in HCC
3个月前
已完结
皖公网安备34019202002308
